Rapport Therapeutics, Inc. RAPP
We take great care to ensure that the data presented and summarized in this overview for Rapport Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RAPP
Top Purchases
Top Sells
About RAPP
Insider Transactions at RAPP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2024
|
James Healy Director |
BUY
Open market or private purchase
|
Indirect |
44,032
+10.4%
|
$1,056,768
$24.59 P/Share
|
|
Jun 10
2024
|
Arch Venture Partners Xii, LLC |
BUY
Conversion of derivative security
|
Indirect |
3,728,738
+50.0%
|
-
|
|
Jun 10
2024
|
Third Rock Ventures V, L.P. |
BUY
Conversion of derivative security
|
Indirect |
969,218
+50.0%
|
-
|
|
Jun 10
2024
|
Third Rock Ventures V, L.P. |
BUY
Conversion of derivative security
|
Direct |
6,551,449
+47.87%
|
-
|
|
Jun 10
2024
|
James Healy Director |
BUY
Open market or private purchase
|
Indirect |
558,824
+44.03%
|
$9,500,008
$17.0 P/Share
|
|
Jun 10
2024
|
James Healy Director |
BUY
Conversion of derivative security
|
Indirect |
1,392,738
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
13.2M
Shares
From
4
Insiders
| Conversion of derivative security | 12.6M shares |
|---|---|
| Open market or private purchase | 603K shares |
Sell / Disposition
0
Shares
From
0
Insiders